2,462 results on '"Felip E"'
Search Results
2. Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
3. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
4. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial
5. Lung cancer research and treatment: global perspectives and strategic calls to action
6. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
7. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
8. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
9. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey
10. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
11. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)
12. Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
13. Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
14. Future care for long-term cancer survivors: towards a new model
15. Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
16. Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’
17. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
18. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)
19. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
20. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
21. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
22. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)
23. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
24. A pragmatic guide for management of adverse events associated with lorlatinib
25. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
26. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
27. 99P Molecular correlates and treatment outcomes of patients with brain metastasis included in early phase trials: A single-center retrospective analysis
28. Efficacité intracrânienne du sotorasib versus docétaxel dans le cancer bronchique non à petites cellules (CBNPC) métastatique muté KRAS G12C données utiles à la pratique issues d’un essai randomisé contrôlé
29. 160TiP Safety and antitumor activity of GEN1042 in combination with pembrolizumab ± chemotherapy in solid tumors: Phase IIb dose-expansion trial in progress
30. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain
31. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients
32. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
33. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus
34. 1541MO Leadership roles in oncology: Gender is still a barrier. Results from the new ESMO Women for Oncology Committee authorship and monitoring studies
35. 1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)
36. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
37. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
38. OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial
39. OA01.05 Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC
40. P2.04-03 EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours
41. OA21.06 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial
42. MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
43. MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC
44. EP07.04-01 Free Circulating and Extracellular Vesicles-Derived microRNA as Prognostic Biomarkers in Resected Early-Stage NSCLC: RESTING Study Results
45. P2.08-01 TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)
46. P2.09-18 FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions
47. OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
48. P2.05-13 Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1
49. EP14.04-02 Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients (p)
50. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.